Ask a Question

You visited our site and still have questions? Feel free to contact us

Consultation and guidance given not in the framework of service does not serve as a replacement for a physician’s examination or consultation, and is not considered a “medical diagnosis” or “medical opinion". In all cases of urgency, distress or emergency (physical and/or mental), seek medical care with a family doctor, closest emergency room, and/or ambulatory service.   

Contact Us


Terms of use

Medix FTP Service (the "Service") is designed to provide you with an easy way to transfer files relevant to the management of your case to Medix Medical Services Europe Limited ("Medix", "we" and "us").


The following terms and conditions together with the Medix Information Security Policy (which may be found at http://medix- (together, the "Terms of Service"), form the agreement between you and us in relation to your use of the Service. You should read the Terms of Service carefully before agreeing to them. If you do not understand any part of the Terms of Services, then please contact us at for further information. You acknowledge and agree that by clicking on the "Upload" button, you are indicating that you accept the Terms of Services and agree to be bound by them.


Using the Service


In order to use the Service, you will be required to log in by submitting your member number which was provided to you by the Medix staff, your name and e-mail address. Once you have logged in, you will be able to upload files to the Service. We will download your files to our system and no copy will be retained on the server used to provide the Service. For detailed upload instructions, please click here.


Protection of your information


We take the safeguarding of your information very seriously. In order to prevent unauthorised access or disclosure of your information we have put in place appropriate physical, electronic and administrative procedures to safeguard and secure the files you upload to the Service. However, no method of transmission over the internet, or method of electronic data storage is 100% secure and while we have put in place appropriate protections, we cannot guarantee the security of information you upload to the Service.


Quality and availability of the Service


While we make reasonable efforts to provide the Service, it is provided "as is" with no representation, guarantee or warranty of any kind as to its availability, functionality, that it will meet your requirements or that it will be free of errors or viruses.


We will not be responsible for any damage to your computer system or the computer system of any third party resulting from your use of the Services where such damage is caused by circumstances which are beyond our reasonable control.


I agree
Contact Us
Contact Us

A New Approach for Fighting Cancer: Treat the immune system, not the tumor


"Science", a world renowned scientific journal, has selected cancer immunotherapy as the medical breakthrough of the year for 2013

You better remember the name “immunotherapy” because it was named “The breakthrough of the year for 2013” by the editors of “Science”.

Despite the fact that the implications of this type of therapy are not fully understood, and the treatment only applies to a small number of cancer patients, the editors of this world renowned journal decided to select immunotherapy for the title. Why?

The journal’s editors believe that immunotherapy has passed the test due to a number of clinical trials which have proven the hidden potential in this treatment modality. These results, coupled with stories of lives extended, have swayed many skeptics: the woman with a grapefruit-size tumor in her lung from melanoma, alive and healthy 13 years later; the 6-year-old near death from leukemia, now in third grade and in remission; the man with metastatic kidney cancer whose disease continued fading away even after treatment stopped.

As the anecdotes coalesce into data, there's another layer, too; a sense of paradigms shifting. Immunotherapy marks an entirely different way of treating cancer - by targeting the immune system, not the tumor itself.

Up until now, the conventional way of treating cancer was trying to attack the tumor; this was done either by surgically removing the tumor when possible, by administering systemic chemotherapy which essentially attacks fast growing cells, cancerous or otherwise, or by applying high doses of radiation to the area of the tumor. Contrarily, immunotherapy involves tweaking and influencing the immune system, either by stimulating it to create more white blood cells, or assisting it with targeting cancerous tissue thus supporting it in battling the cancer. The revelation that another dimension to the fight against cancer exists is what led "Science" to name immunotherapy a breakthrough.

The first steps were made thanks to the discovery of James Alison, an American cancer immunologist, who found a protein receptor in a kind of white blood cells called T cells, which puts the brakes on these cells, preventing them from launching full-out attacks on disease.

Bristol-Myers Squibb, an international pharmaceutical company, used a drug which counteracts this process, thus strengthening the immune system and reported that patients with metastatic melanoma lived an average of 10 months with the treatment, compared with 6 months without it. It was the first time any treatment had extended life in advanced melanoma in a randomized trial. Nearly a quarter of participants survived at least 2 years. Based on the same logic, a number of other drugs are being developed which have a higher success rate and are associated with less side effects.

Today, both the FDA in America and NICE have approved Bristol-Myers Squibb's immunotherapy drug, called Ipilimumab, for metastatic melanoma. Last year they reported that of 1,800 melanoma patients treated with Ipilimumab, 22% were still alive 3 years later.

Today’s immunotherapy doesn’t help everyone, and researchers are constantly trying to understand why in order to create more potent treatments. Even in the state of uncertainty surrounding certain aspects of immunotherapy one thing is certain, one book has closed, and a new one has opened.

By continuing to use this site you consent to the use of cookies on your device as described in our cookie policy unless you have disabled them. You can change your cookie settings at any time but parts of our site will not function correctly without them.